Verapamil

Verapamil (a Class IV antiarrhythmic agent) belongs to the calcium channel blockers. Along with diltiazem, these are the medications within this class that exert direct myocardial effects, in contrast to other calcium channel blockers which primarily exhibit peripheral vasodilatory action. Verapamil can be administered both orally and intravenously. It exerts a more pronounced effect on the sinus node, inducing sinus bradycardia, and on the atrioventricular (AV) node, resulting in decreased conduction velocity. For this reason, it can be indicated for the cardioversion or prevention of reentrant tachycardias whose circuit involves the AV node.

Indications

  • In its intravenous form, it can be administered for the immediate termination (cardioversion) of supraventricular tachycardias, such as atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) involving an accessory pathway.
  • In its oral form, it can be prescribed for the prevention of supraventricular tachycardias.
  • Verapamil may be administered for ventricular rate control in patients presenting with atrial fibrillation or atrial flutter and rapid ventricular response; however, the drug does not exert any effect on converting atrial fibrillation back to normal sinus rhythm.
  • Less frequently, it is recommended for the prevention of ventricular arrhythmias, typically idiopathic, in patients without concomitant heart failure.
  • Intravenous therapy with verapamil can terminate so-called "fascicular" ventricular tachycardia originating from the left ventricle. However, the administration of verapamil in wide QRS complex tachycardias can become highly dangerous if there is no absolute diagnostic certainty that it represents the aforementioned specific form.
  • It may be administered in cases of ventricular tachycardias secondary to coronary artery spasm.

Adverse Effects

  • Its administration is strictly contraindicated in patients diagnosed with heart failure.
  • Hypotension, bradycardia, atrioventricular (AV) block, and asystole may occur, particularly when co-administered with beta-blockers.
2026-11-18T22:41:05+00:00